Aldebaran Capital’s enGene Therapeutics ENGN Stock Holding History

Aldebaran Capital’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.31M	Buy	+657,319	New	+$1.22M	0.95%	27

Other funds holding ENGN

BCM

BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return

F.L. Putnam Investment Management Lynnfield, Massachusetts $9.33B AUM 30.52% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return

Quadrature Capital London, United Kingdom $16.1B AUM 61.25% 1-Year Est. Return

Aldebaran Capital's ENGN Position: Q3 2026 in Review

Aldebaran Capital opened a new position in enGene Therapeutics (ENGN) in Q3 2026: 657,319 shares worth $1.31M. The stake represents 0.95% of the portfolio and ranks #27 among its holdings.

33 funds tracked by Wall St. Rank hold ENGN as of Q3 2026.

Aldebaran Capital held 657,319 shares of enGene Therapeutics worth $1.31M as of Q3 2026.
enGene Therapeutics was a new Aldebaran Capital position in Q3 2026.
enGene Therapeutics made up 0.95% of Aldebaran Capital's portfolio in Q3 2026, its #27 holding.
33 funds tracked by Wall St. Rank held enGene Therapeutics as of Q3 2026.

Based on Aldebaran Capital's 13F filing for Q3 2026, filed 13 Nov 2026.